Other Events ·
Nasdaq notifies Kyntra Bio of non-compliance with $50M asset and revenue listing standards
FGENFibrogen Inc
On September 30, 2026, Nasdaq notified Kyntra Bio that it failed to meet the continued listing requirements under Rule 5450(b), specifically lacking the required $50 million in total assets and total revenue for the most recent fiscal years. The company has timely requested a hearing before a Nasdaq Hearings Panel to seek an extension of up to 180 days to regain compliance, which stays any immediate delisting action pending the panel's decision. Kyntra Bio operates as a biotechnology company focused on developing therapeutic treatments.